Literature DB >> 10211989

Significance of trisomy 7 and 12 in thyroid lesions with follicular differentiation: a cytogenetic and in situ hybridization study.

L Roque1, A Serpa, A Clode, S Castedo, J Soares.   

Abstract

In a group of benign and malignant follicular thyroid lesions, previously analyzed by conventional cytogenetics, single- and double-target fluorescence in situ hybridization studies with pericentromeric probes specific for chromosomes 7 and 12 were performed, by using isolated nuclei from paraffin-embedded specimens of: 11 goiters, 21 adenomas, 9 follicular carcinomas, and adjacent normal thyroid tissue. Nonisotopic in situ hybridization with the same probes was used in 4-microm histologic sections of four follicular carcinomas. By fluorescence in situ hybridization analysis, the percentage of goiters, adenomas, and follicular carcinomas with gains of No. 7 was 18.2%, 52.4%, and 66.0%, respectively, and with gains of No. 12 was 9.0%, 42.9%, and 66.0%, respectively. The percentage of the same lesions (goiters, adenomas, carcinomas) exhibiting polysomies of No. 7 and No. 12, as assessed by cytogenetic analysis, was 5.0% and 0.0%, 20.0% and 20.0%, and 15.8% and 10.5%, respectively. Numerical alterations of these chromosomes were not observed in normal tissue. These findings reveal that gain of chromosomes 7 and 12 is a characteristic of the morphologically altered thyroid tissue; polysomies of chromosomes 7 and 12 are more frequent in thyroid lesions than it can be detected by conventional cytogenetic studies; the increasing frequency of polysomies of chromosomes 7 and 12 from hyperplastic lesions to benign and malignant tumors seem to substantiate the existence of a multistep pathway, ie, normal thyroid --> goiter --> adenoma --> follicular carcinoma in the pathogenesis of some thyroid neoplasms.

Entities:  

Mesh:

Year:  1999        PMID: 10211989

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  6 in total

1.  The Art and Applications of Fluorescence In Situ Hybridization in Endocrine Pathology.

Authors:  George Kontogeorgos
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

2.  Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.

Authors:  Brendan D Looyenga; Kyle A Furge; Karl J Dykema; Julie Koeman; Pamela J Swiatek; Thomas J Giordano; Andrew B West; James H Resau; Bin T Teh; Jeffrey P MacKeigan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

3.  Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation.

Authors:  J Nicholson; C Wickramasinghe; F Ross; J Crolla; D Ellison
Journal:  Mol Pathol       Date:  2000-12

4.  Genomic differences in benign and malignant follicular thyroid tumours using 1-Mb array-comparative genomic hybridisation.

Authors:  Abdul A Qureshi; V P Collins; P Jani
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-04-13       Impact factor: 2.503

Review 5.  Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.

Authors:  María San Román Gil; Javier Pozas; Javier Molina-Cerrillo; Joaquín Gómez; Héctor Pian; Miguel Pozas; Alfredo Carrato; Enrique Grande; Teresa Alonso-Gordoa
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

6.  RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient.

Authors:  Rozita Bagheri-Yarmand; Naifa L Busaidy; Elena McBeath; Brian P Danysh; Kurt W Evans; Tyler J Moss; Argun Akcakanat; Patrick K S Ng; Christina M Knippler; Jalyn A Golden; Michelle D Williams; Asha S Multani; Maria E Cabanillas; Kenna R Shaw; Funda Meric-Bernstam; Manisha H Shah; Matthew D Ringel; Marie Claude Hofmann
Journal:  Cancers (Basel)       Date:  2021-09-30       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.